Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Acquires 26,963 Shares

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe purchased 26,963 shares of the stock in a transaction on Thursday, September 12th. The shares were acquired at an average cost of $15.05 per share, for a total transaction of $405,793.15. Following the transaction, the chief executive officer now owns 692,511 shares of the company’s stock, valued at $10,422,290.55. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Lappe also recently made the following trade(s):

• On Monday, September 16th, Mark Lappe bought 13,037 shares of Inhibrx stock. The shares were acquired at an average cost of $17.13 per share, for a total transaction of $223,323.81.
• On Monday, September 9th, Mark Lappe purchased 9,500 shares of Inhibrx stock. The shares were acquired at an average cost of $15.21 per share, with a total value of $144,495.00.
• On Friday, September 6th, Mark Lappe acquired 26,000 shares of Inhibrx stock. The stock was bought at an average price of $15.29 per share, for a total transaction of $397,540.00.
• On Tuesday, September 3rd, Mark Lappe bought 20,000 shares of Inhibrx stock. The shares were bought at an average price of $15.81 per share, with a total value of $316,200.00.
• On Thursday, August 29th, Mark Lappe purchased 10,000 shares of Inhibrx stock. The stock was bought at an average cost of $14.03 per share, for a total transaction of $140,300.00.

Inhibrx Trading Up 6.2 %

Shares of INBX stock traded up $1.02 on Monday, hitting $17.43. The company’s stock had a trading volume of 186,839 shares, compared to its average volume of 176,803. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $18.95. The stock’s 50 day moving average is $13.63 and its 200-day moving average is $23.74.

Inhibrx (NASDAQ:INBX) last announced its earnings results on Tuesday, August 13th. The company reported $125.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million for the quarter. As a group, sell-side analysts anticipate that Inhibrx, Inc. will post 87.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities initiated coverage on Inhibrx in a research report on Tuesday, July 23rd. They issued a “market perform” rating on the stock.

Institutional Investors Weigh In On Inhibrx

A number of large investors have recently added to or reduced their stakes in INBX. Black Maple Capital Management LP bought a new stake in shares of Inhibrx during the 1st quarter valued at $555,000. Price T Rowe Associates Inc. MD lifted its position in Inhibrx by 8.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 14,812 shares of the company’s stock worth $518,000 after purchasing an additional 1,112 shares during the period. Alpine Global Management LLC acquired a new stake in Inhibrx during the first quarter worth about $1,224,000. MMCAP International Inc. SPC acquired a new stake in Inhibrx during the first quarter worth about $15,782,000. Finally, Entropy Technologies LP bought a new position in Inhibrx in the 1st quarter valued at about $384,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.